Axsome Therapeutics, Inc.
AXS-12
cataplexy in narcolepsy
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on AXS-12 for cataplexy in narcolepsy is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“NDA for AXS-12 for the treatment of cataplexy in narcolepsy submitted to the FDA”